Credit Suisse Group reaffirmed their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Monday morning, Marketbeat.com reports. Credit Suisse Group currently has a $207.00 price target on the biotechnology company’s stock, up from their previous price target of $189.00.

A number of other analysts also recently commented on the company. HC Wainwright set a $267.00 price objective on Sarepta Therapeutics and gave the stock a buy rating in a research report on Monday, December 10th. BidaskClub upgraded Sarepta Therapeutics from a hold rating to a buy rating in a research report on Monday, February 4th. Royal Bank of Canada reiterated an outperform rating and issued a $164.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, January 17th. Cantor Fitzgerald reiterated a buy rating and issued a $217.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, November 26th. Finally, Morgan Stanley raised their price objective on Sarepta Therapeutics from $161.00 to $169.00 and gave the stock an overweight rating in a research report on Monday, March 4th. Four analysts have rated the stock with a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $189.86.

Shares of SRPT stock opened at $129.41 on Monday. The company has a quick ratio of 7.49, a current ratio of 8.21 and a debt-to-equity ratio of 0.41. Sarepta Therapeutics has a 12 month low of $70.50 and a 12 month high of $176.50. The company has a market capitalization of $9.55 billion, a price-to-earnings ratio of -23.70 and a beta of 2.08.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.85) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.08) by $0.23. Sarepta Therapeutics had a negative return on equity of 36.73% and a negative net margin of 120.22%. The company had revenue of $84.40 million during the quarter, compared to the consensus estimate of $84.83 million. During the same quarter last year, the company earned ($0.37) EPS. The company’s quarterly revenue was up 47.3% on a year-over-year basis. On average, equities research analysts forecast that Sarepta Therapeutics will post -5.17 EPS for the current year.

In related news, SVP David T. Howton sold 30,000 shares of the firm’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $140.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the senior vice president now directly owns 31,196 shares of the company’s stock, valued at approximately $4,367,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sandesh Mahatme sold 65,000 shares of the firm’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $145.00, for a total value of $9,425,000.00. Following the sale, the chief financial officer now directly owns 73,649 shares of the company’s stock, valued at $10,679,105. The disclosure for this sale can be found here. Insiders have sold a total of 160,000 shares of company stock valued at $22,089,950 in the last 90 days. 7.90% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. grew its stake in shares of Sarepta Therapeutics by 4.6% during the fourth quarter. American Century Companies Inc. now owns 425,580 shares of the biotechnology company’s stock worth $46,444,000 after purchasing an additional 18,760 shares during the period. Geode Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 11.4% during the fourth quarter. Geode Capital Management LLC now owns 658,753 shares of the biotechnology company’s stock worth $71,889,000 after purchasing an additional 67,601 shares during the period. Norges Bank acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $57,891,000. Dimensional Fund Advisors LP grew its stake in shares of Sarepta Therapeutics by 3.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 160,044 shares of the biotechnology company’s stock worth $17,465,000 after purchasing an additional 4,602 shares during the period. Finally, FMR LLC grew its stake in shares of Sarepta Therapeutics by 6.9% during the fourth quarter. FMR LLC now owns 10,565,177 shares of the biotechnology company’s stock worth $1,152,977,000 after purchasing an additional 677,947 shares during the period.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Featured Article: Dividend

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.